Structure-Activity Relationship Study of Splicing Modulators on Hsh155/SF3B1 through Chemical Synthesis and Yeast...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Meayamycins are synthetic analogs of FR901464 with demonstrated anticancer properties.
• These compounds function by binding to SF3B1 and PHF5A, key components of the human spliceosome, thereby modulating pre-mRNA splicing.

Purpose of the Study:

• To synthesize and evaluate novel meayamycin analogs with modifications in the α,β-unsaturated amide region.
• To investigate the specific interactions between meayamycins and the SF3B1 protein, particularly within a narrow binding pocket.

Main Methods:

• Synthesis of two new meayamycin analogs with methyl substituents at the α or β position of the amide.
• Utilizing a human/yeast chimeric SF3B1 protein to probe discrete interactions within the SF3B1 binding site.
• Assessing the biological activity and binding characteristics of the synthesized analogs.

Main Results:

• The synthesized analogs were evaluated for their anticancer activity and binding to SF3B1.
• The study identified that the V1078 residue of SF3B1 plays a significant role in the binding of meayamycins to the amide moiety.
• This residue's interaction is critical for the compound's ability to alter splicing.

Conclusions:

• The V1078 residue in SF3B1 is a key determinant for meayamycin binding and efficacy.
• Understanding these specific interactions can guide the design of more potent and selective anticancer agents targeting the spliceosome.